Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of AFQ056 in Reducing L-Dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-Dopa
This study is ongoing, but not recruiting participants.
Study NCT00582673   Information provided by Novartis
First Received: December 21, 2007   Last Updated: May 9, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson's Disease
Additional conditions recognized in this trial
Dyskinesias
Parkinson Disease
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Parkinsonian Disorders
Signs and Symptoms
Interventions listed in this trial
AFQ056
Placebo
Additional drug interventions recognized in this trial
Levodopa
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services